Skip to main content
Top
Published in: Pathology & Oncology Research 3/2018

01-07-2018 | Short Communication

Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors

Authors: Sofia S. Pereira, Madalena M. Costa, Susana G. Guerreiro, Mariana P. Monteiro, Duarte Pignatelli

Published in: Pathology & Oncology Research | Issue 3/2018

Login to get access

Abstract

Adrenocortical tumors (ACT) are common adrenal tumors. The majority of ACTs are non-functioning and benign, while adrenocortical carcinomas (ACC) are rare, usually very aggressive and often metastasized when first diagnosed. Our aim was to assess whether blood and lymph vessel density within ACTs correlate with the malignancy character or tumor functionality. For that, the microvascular distribution was evaluated by immunohistochemistry staining with D2–40 antibody, for lymph vessels and CD-31 antibody, for blood vessels, in ACCs (n = 15), adenomas with Cushing syndrome (n = 9) and non-functioning adenomas (n = 10). The percentage of stained area was quantified by computerized morphometric analysis. D2–40 expression was significantly lower in ACC as compared to adenomas with Cushing syndrome (p < 0.01) and correlated positively with the expression of the steroidogenic acute regulatory protein (StAR) (R2 = 0.553, p < 0.001). CD31 expression was found to be significantly higher in ACC as compared to adenomas with Cushing syndrome (p < 0.05). Our results show that angiogenesis is increased in ACC, suggesting that this phenomenon may have an important role in ACT biological behavior, while lymph vascular density seems to be more closely related to the tumor functional status than malignancy.
Literature
1.
go back to reference Allolio B, Hahner S, Weismann D, Fassnacht M (2004) Management of adrenocortical carcinoma. Clin Endocrinol 60(3):273–287CrossRef Allolio B, Hahner S, Weismann D, Fassnacht M (2004) Management of adrenocortical carcinoma. Clin Endocrinol 60(3):273–287CrossRef
4.
5.
go back to reference Browning L, Bailey D, Parker A (2008) D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol 61(3):293–296. doi:10.1136/jcp.2007.049544 CrossRefPubMed Browning L, Bailey D, Parker A (2008) D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol 61(3):293–296. doi:10.​1136/​jcp.​2007.​049544 CrossRefPubMed
6.
go back to reference Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P, Salvetti A (2002) Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab 87(11):4961–4965. doi:10.1210/jc.2001-011799 CrossRefPubMed Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P, Salvetti A (2002) Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab 87(11):4961–4965. doi:10.​1210/​jc.​2001-011799 CrossRefPubMed
7.
go back to reference Zhu Y, Xu Y, Chen D, Zhang C, Rui W, Zhao J, Zhu Q, Wu Y, Shen Z, Wang W, Ning G, Wang X (2014) Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis. Clin Transl Oncol 16(7):644–649. doi:10.1007/s12094-013-1130-1 CrossRefPubMed Zhu Y, Xu Y, Chen D, Zhang C, Rui W, Zhao J, Zhu Q, Wu Y, Shen Z, Wang W, Ning G, Wang X (2014) Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis. Clin Transl Oncol 16(7):644–649. doi:10.​1007/​s12094-013-1130-1 CrossRefPubMed
10.
go back to reference De Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz E, Feige J (2000) Expression of the angiogenesis markers vascular endothelial growth factor-a, Thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations 1. J Clin Endocrinol Metab 85(12):4734–4741PubMed De Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz E, Feige J (2000) Expression of the angiogenesis markers vascular endothelial growth factor-a, Thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations 1. J Clin Endocrinol Metab 85(12):4734–4741PubMed
11.
go back to reference Moreira A, Pereira SS, Machado CL, Morais T, Costa M, Monteiro MP (2014) Obesity inhibits lymphangiogenesis in prostate tumors. Int J Clin Exp Pathol 7(1):348–352PubMed Moreira A, Pereira SS, Machado CL, Morais T, Costa M, Monteiro MP (2014) Obesity inhibits lymphangiogenesis in prostate tumors. Int J Clin Exp Pathol 7(1):348–352PubMed
12.
go back to reference Ozerdem U, Wojcik EM, Duan X, Ersahin C, Barkan GA (2013) Prognostic utility of quantitative image analysis of microvascular density in prostate cancer. Pathol Int 63(5):277–282. doi:10.1111/pin.12056 CrossRefPubMed Ozerdem U, Wojcik EM, Duan X, Ersahin C, Barkan GA (2013) Prognostic utility of quantitative image analysis of microvascular density in prostate cancer. Pathol Int 63(5):277–282. doi:10.​1111/​pin.​12056 CrossRefPubMed
13.
go back to reference Pereira F, Pereira SS, Mesquita M, Morais T, Costa MM, Quelhas P, Lopes C, Monteiro MP, Leite V (2017) Lymph node metastases in papillary and medullary thyroid carcinoma are independent of Intratumoral lymphatic vessel density. European Thyroid Journal 6(2):57–64CrossRefPubMedPubMedCentral Pereira F, Pereira SS, Mesquita M, Morais T, Costa MM, Quelhas P, Lopes C, Monteiro MP, Leite V (2017) Lymph node metastases in papillary and medullary thyroid carcinoma are independent of Intratumoral lymphatic vessel density. European Thyroid Journal 6(2):57–64CrossRefPubMedPubMedCentral
Metadata
Title
Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors
Authors
Sofia S. Pereira
Madalena M. Costa
Susana G. Guerreiro
Mariana P. Monteiro
Duarte Pignatelli
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0259-6

Other articles of this Issue 3/2018

Pathology & Oncology Research 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine